Logo image of XRTX

XORTX THERAPEUTICS INC (XRTX) Stock Fundamental Analysis

NASDAQ:XRTX - Nasdaq - CA98420Q3061 - Common Stock - Currency: USD

0.89  -0.02 (-2.2%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XRTX. XRTX was compared to 195 industry peers in the Pharmaceuticals industry. XRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XRTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XRTX had negative earnings in the past year.
XRTX had a negative operating cash flow in the past year.
XRTX had negative earnings in each of the past 5 years.
XRTX had a negative operating cash flow in each of the past 5 years.
XRTX Yearly Net Income VS EBIT VS OCF VS FCFXRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

With a decent Return On Assets value of -19.13%, XRTX is doing good in the industry, outperforming 63.98% of the companies in the same industry.
With a decent Return On Equity value of -34.53%, XRTX is doing good in the industry, outperforming 65.05% of the companies in the same industry.
Industry RankSector Rank
ROA -19.13%
ROE -34.53%
ROIC N/A
ROA(3y)-36.45%
ROA(5y)-44.66%
ROE(3y)-55.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XRTX Yearly ROA, ROE, ROICXRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX Yearly Profit, Operating, Gross MarginsXRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for XRTX has been increased compared to 1 year ago.
Compared to 5 years ago, XRTX has less shares outstanding
The debt/assets ratio for XRTX has been reduced compared to a year ago.
XRTX Yearly Shares OutstandingXRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
XRTX Yearly Total Debt VS Total AssetsXRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

XRTX has an Altman-Z score of -8.20. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.20, XRTX is doing worse than 71.51% of the companies in the same industry.
There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.2
ROIC/WACCN/A
WACCN/A
XRTX Yearly LT Debt VS Equity VS FCFXRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 1.40 indicates that XRTX should not have too much problems paying its short term obligations.
XRTX's Current ratio of 1.40 is on the low side compared to the rest of the industry. XRTX is outperformed by 76.88% of its industry peers.
XRTX has a Quick Ratio of 1.40. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.40, XRTX is doing worse than 68.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
XRTX Yearly Current Assets VS Current LiabilitesXRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.62% over the past year.
EPS 1Y (TTM)98.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XRTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.31%
EPS Next 2Y-4.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX Yearly Revenue VS EstimatesXRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
XRTX Yearly EPS VS EstimatesXRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX Price Earnings VS Forward Price EarningsXRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX Per share dataXRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A cheap valuation may be justified as XRTX's earnings are expected to decrease with -4.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.43%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XORTX THERAPEUTICS INC

NASDAQ:XRTX (2/5/2025, 3:25:49 PM)

0.89

-0.02 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners6.37%
Inst Owner Change0%
Ins Owners3.11%
Ins Owner ChangeN/A
Market Cap3.10M
Analysts80
Price TargetN/A
Short Float %2.75%
Short Ratio0.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.69
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.61
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.13%
ROE -34.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.45%
ROA(5y)-44.66%
ROE(3y)-55.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -8.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)111.48%
Cap/Depr(5y)88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.69%
EPS Next Y2.31%
EPS Next 2Y-4.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-49.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.55%
OCF growth 3YN/A
OCF growth 5YN/A